Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Serine/Threonine Protein Kise Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Overview
Serine/Threonine Protein Kise Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Serine/Threonine Protein Kise Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Serine/Threonine Protein Kise Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Incyte Corp
Inflection Biosciences Ltd
NewBay Medical Technology Co Ltd
Novartis AG
Onconova Therapeutics Inc
Shengke Pharmaceuticals (Jiangsu) Ltd
Sumitomo Dainippon Pharma Oncology, Inc
X-37 LLC
Yakult Honsha Co Ltd
Serine/Threonine Protein Kise Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Drug Profiles
ETH-155008 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GDC-0570 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IBL-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
INCB-53914 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LGB-321 - Drug Profile
Product Description
Mechanism Of Action
ON-108110 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit PIM1, PIM2 and PIM3 for Solid Tumors and Hematological Tumors - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit PIM1 and PIM3 for Hematological Cancers - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit PIM3 for Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
TP-3654 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Serine/Threonine Protein Kise Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Dormant Products
Serine/Threonine Protein Kise Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Discontinued Products
Serine/Threonine Protein Kise Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Apr 10, 2021: Sumitomo Dainippon Pharma Oncology presents on TP-3654 at AACR Virtual Annual Meeting I 2021
May 29, 2020: Tolero Pharmaceuticals presents findings from first clinical studies evaluating investigatiol agent TP-3654 in patients with advanced solid tumors at ASCO Virtual Annual Meeting 2020
Apr 06, 2020: Boston Biomedical announces first patient dosed in phase 1 study of investigatiol agent TP-3654 in patients with myelofibrosis
May 14, 2019: Tolero Pharmaceuticals announces first patient dosed in phase 1 study of investigatiol agent TP-3654 in patients with advanced solid tumors
Oct 23, 2017: Tolero Pharma To Present Preclinical Data Supporting Development of Cancer Drug Candidate TP-3654 for Myc-dependent Triple Negative Breast Cancer
Oct 05, 2017: Tolero Pharma to Deliver Keynote Presentations at 9th Intertiol Conference on Leukemia and Hematologic Oncology
Jun 30, 2014: Tolero’s PIM Kise Inhibitor Demonstrates Promising Activity in Preclinical Models of Urothelial Carcinoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Incyte Corp, 2022
Pipeline by Inflection Biosciences Ltd, 2022
Pipeline by NewBay Medical Technology Co Ltd, 2022
Pipeline by Novartis AG, 2022
Pipeline by Onconova Therapeutics Inc, 2022
Pipeline by Shengke Pharmaceuticals (Jiangsu) Ltd, 2022
Pipeline by Sumitomo Dainippon Pharma Oncology, Inc, 2022
Pipeline by X-37 LLC, 2022
Pipeline by Yakult Honsha Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022